Postmarket safety of drugs approved by Health Canada on the basis of clinical and surrogate outcomes: a cohort study

Abstract

Background: Health Canada approves drugs on the basis of evidence from clinical trials using clinical or surrogate outcomes. This study compares the postmarket safety of these 2 groups of drugs.Methods: Information about whether clinical or surrogate outcomes were used and the date of market approval were obtained from Health Canada's Summary Basis of Decision documents issued from Jan. 1, 20051, , to Dec. 31, 2014. Safety warnings and the dates they were issued were identified through advisories on the MedEffect Canada website. Kaplan-Meier survival curves were calculated to determine the likelihood that drugs in the clinical and surrogate outcome groups would receive a serious safety warning. The time from market authorization to first serious safety warning was compared for the 2 groups of drugs.Results: A total of 124 drugs were approved by Health Canada using clinical outcomes and 114 using surrogate outcomes. KaplanMeier curves did not differ between the 2 groups (p < 0.9). The median time from market authorization to first serious safety warning was 722 days in the clinical outcome group and 818 days in the surrogate outcome group (difference 96 days, 95% confidence interval -295 to 425). Interpretation:We found no statistically significant difference in postmarket safety between drugs approved using clinical outcomes and those approved using surrogate outcomes. Because drugs in the surrogate outcome group are approved before their benefit:harm ratio is fully established, these drugs should be used with caution until their clinical benefits are better understood. AbstractResearch CMAJ OPEN CMAJ OPEN, 3(3)

Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis

“…Almost 20% of drugs will eventually acquire a new serious safety warning 9 and from 1990 to 2009, between 4% and 5% approved in a 5-year period were eventually removed from the Canadian market because of safety reasons. 10 Just under 50% of new drug approvals in Canada are based on trials with surrogate end points 11 and surrogate outcomes are often not a reliable indicator of the true efficacy/effectiveness of new drugs. 12 The uncertainty about safety and efficacy can complicate listing decisions about all new drugs, but even more so for those with an NOC/c approval.…”

Unwarranted claims of drug efficacy in pharmaceutical sales visits: are drugs approved on the basis of surrogate outcomes promoted appropriately?

“…The use of surrogate outcomes is widespread in pre‐marketing studies. In Canada, 114 out of 238 new drug approvals were based on surrogate outcomes between 2005 and 2014 . In the US, between 2005 and 2012, 91 out of 201 indications (45%) for 188 new drugs were approved on the basis of trials that used surrogate outcomes as the primary outcome measure .…”